SUVEN360.00

Suven Life Sciences Limited

· Pharma & Health
₹ CrorePeersVIMTALABSTAKEMcap ₹9,494 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation5.85.35.6
+ Finance Costs0.20.00.2
+ Interest Income16.4-5.7-4.2
+ Fair Value (Gains) / Losses-4.5-5.0-9.5
+ Share-based Payments0.01.31.8
+ Unrealised FX (Gain) / Loss0.00.00.2
+ Other Reconciling Items-7.50.0-0.4
Changes in Working Capital
+ Inventories-0.70.50.1
+ Trade Receivables — Current-0.5-0.1-0.2
+ Other Current Assets5.1-1.9-8.7
+ Other Non-current Assets0.90.5-0.0
+ Trade Payables — Current0.43.2-0.7
+ Other Financial Liabilities — Current2.26.9-10.4
+ Other Current Liabilities-0.00.11.6
+ Provisions — Current0.00.5-0.3
+ Provisions — Non-current-0.50.40.2
Cash from Operating Activities
Profit Before Tax (per I/S)-106.1-160.7-276.3-352.4
+ Total Adjustments (incl. Working Capital)17.36.0-24.7
Cash from Operations (pre-tax)-88.8-154.7-301.0
+ Income Taxes Paid-6.2-0.60.8
Cash from Operating Activities-82.6-154.1-301.8
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)-2.437.35.1
+ Dividends Received — Investing-16.40.00.0
+ Interest Received — Investing0.05.74.2
+ Other Inflows / (Outflows) — Investing75.6186.5-461.3
Cash from Investing Activities61.6155.0-462.1
Cash from Financing Activities
+ Proceeds from Issue of Shares0.00.0757.2
+ Payment of Lease Liabilities0.90.70.0
+ Interest Paid0.20.00.0
Cash from Financing Activities-1.1-0.8757.2
Net Changes in Cash (pre-FX)-22.10.1-6.7
Net Changes in Cash-22.10.1-6.7
Closing Cash14.9
Reference Items
EBITDA-128.0-165.8-284.5-366.3
EBITDA Margin %-1,094.72-2,490.66-3,998.80-4,155.50
Free Cash Flow (CFO − Capex)-80.2-191.4-306.9-306.9
Free Cash Flow to Equity-191.4-306.9
Free Cash Flow per Basic Share-3.04-7.26-11.64-11.64
Cash Flow to Net Income0.790.961.09
Cash Paid for Taxes-6.2-0.60.8
Cash Paid for Interest0.20.00.0
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.